Arosh, Joe A <br/><br/>
Molecular and preclinical basis to inhibit PGE2 receptors EP2 and EP4 as a novel nonsteroidal therapy for endometriosis.  [electronic resource] 

 -  Proceedings of the National Academy of Sciences of the United States of America  Aug 2015 
 - 9716-21 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1091-6490 
<br/><br/><label>Standard No.: </label>10.1073/pnas.1507931112  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Apoptosis--drug effects<br/>Biphenyl Compounds--pharmacology<br/>Caspase 3--metabolism<br/>Cell Line<br/>Cell Movement--drug effects<br/>Cell Survival--drug effects<br/>Disease Models, Animal<br/>Endometriosis--drug therapy<br/>Endometrium--blood supply<br/>Estrogens--biosynthesis<br/>Female<br/>Humans<br/>Inflammation--pathology<br/>Mice<br/>Neovascularization, Pathologic--metabolism<br/>Pelvic Pain--drug therapy<br/>Poly(ADP-ribose) Polymerases--metabolism<br/>Progesterone--metabolism<br/>Receptors, Prostaglandin E, EP2 Subtype--antagonists & inhibitors<br/>Receptors, Prostaglandin E, EP4 Subtype--antagonists & inhibitors<br/>Signal Transduction--drug effects<br/>Steroids--therapeutic use<br/>Xanthones--pharmacology